



Pharming Group N.V.
Extraordinary General
Meeting 2023

September 25, 2023

NASDAQ: PHAR | EURONEXT Amsterdam: PHARM

This presentation may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", "anticipate", "believe", "could", "estimate", "expect", "goals", "intend", "may", "milestones", "objectives", "outlook", "plan", "probably", "project", "risks", "schedule", "seek", "should", "target", "will" and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2022 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this presentation are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this presentation and are based on information available to Pharming as of the date of this presentation. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

1. Opening and announcements

2. Appointment Non-Executive Director *(voting item)*

Proposal to appoint Dr. Richard Peters, upon binding nomination of the Board of Directors, as Non-Executive Director for a period of four years

3. Remuneration New Chair *(voting item)*

Proposal to approve, by way of a supplement to the current Remuneration Policy for the Board of Directors, the increase of the annual fee payable to the Chair of the Board of Directors by EUR 25,000, resulting in an annual amount of EUR 90,000 in cash (currently EUR 65,000) and the annual grant of EUR 40,000 in unrestricted ordinary shares (unchanged), subject to the appointment of Dr. Richard Peters as Non-Executive Director under agenda item 2 and the remaining provisions of the applicable Remuneration Policy.

4. Any other business *(discussion item)*

5. Closing

1. Opening and announcements *(discussion item)*



Jabine van der Meijs

Non-Executive Director,
Chairperson of the Corporate
Governance Committee, Member
of the Audit Committee and
Member of the Remuneration
Committee



Sijmen de Vries, MD, MBA

Executive Director
& Chief Executive Officer



Paul Sekhri

Chairman of the Board of Directors &
Member of the Corporate Governance Committee



Deborah Jorn, MBA

Vice-Chair of the Board of Directors, Member
of the Remuneration Committee & Member of
the Audit Committee



Barbara Yanni

Non-Executive Director, Chairperson of the
Transaction Committee, Member of the Audit
Committee & the Corporate Governance Committee



Mark Pykett, VMD, PhD

Non-Executive Director, Member of the
Remuneration Committee & Member of the
Transaction Committee



Leonard Kruimer

Non-Executive Director, Chairperson of the Audit
Committee & Member of the Transaction Committee



Jabine van der Meijs

Non-Executive Director, Chairperson of the
Corporate Governance Committee, Member of the
Audit Committee & Remuneration Committee



Steven Baert

Non-Executive Director, Chairperson of the
Remuneration Committee & Member of
the Corporate Governance Committee

Leadership: Executive Committee



Sijmen de Vries, MD MBA
Executive Director &
Chief Executive Officer



Jeroen Wakkerman
Chief Finance Officer



Anurag Relan MD
Chief Medical Officer



Mireille Sanders MSc
Chief Operations Officer



Stephen Toor
Chief Commercial Officer



Ruud van Outersterp
Chief Ethics &
Compliance Officer



**Dr. Alexander
Breidenbach, MBA**
Chief Business Officer



2. Appointment of Non-Executive Director

(voting item)

Proposal to appoint Dr. Richard Peters, upon binding nomination of the Board of Directors, as Non-Executive Director for a period of four years

Once the voting on the agenda item is open

Press **“FOR”** to vote **IN FAVOR** of the proposal

OR

Press **“AGAINST”** to vote **AGAINST** the proposal


OR

Press **“ABSTAIN”** if you **wish NOT VOTE** in favor of or against the proposal.

You may change your vote until the voting is closed

Proposal, by way of binding nomination, to appoint Dr. Richard Peters as Non-Executive Director for a period of four years

For	148,403,789
Against	83,033
Abstain	460,870

For	 99.94%
Against	0.06%





Steven Baert

Non-Executive Director, Chair of
the Remuneration Committee
and Member of the Corporate
Governance Committee


3. Remuneration new chair

(voting item)

Proposal to approve, by way of a supplement to the current Remuneration Policy for the Board of Directors, the increase of the annual fee payable to the Chair of the Board of Directors by EUR 25,000, resulting in an annual amount of EUR 90,000 in cash (currently EUR 65,000) and the annual grant of EUR 40,000 in unrestricted ordinary shares (unchanged), subject to the appointment of Dr. Richard Peters as Non-Executive Director under agenda item 2 and the remaining provisions of the applicable Remuneration Policy.

Proposal to approve the increase of the annual fee payable to the new Chair of the Board of Directors by EUR 25,000, resulting in an annual amount of EUR 90,000 in cash (currently EUR 65,000) and the annual grant of EUR 40,000 in unrestricted ordinary shares (unchanged), subject to the appointment of Dr. Richard Peters as NonExecutive Director under agenda item 2.

For	144,589,000
Against	1,306,063
Abstain	3,052,629

For	 99.10%
Against	0.90%



4. Any other business

(discussion item)



5. Closing

www.pharming.com | investor@pharming.com

NASDAQ: **PHAR** | Euronext Amsterdam: **PHARM**

Bloomberg: **PHAR.AS**